Suntory has stepped forward to make this attractive hormone available to patients with this disease, which is widely prevalent in the world. Non-confidential and confidential packages are ready for review. This approach is based on the premise that supplying large amounts of peptides at low cost is difficult to be attained. Therefore, companies have been hesitant to pursue non-parenteral administration of peptides, because the companies would be require to produce large quantities of peptides continually at low cost to meet the demand in the market. We believe that human natural peptides are best suited to the body for absorption, exertion of bioactivities, and excretion.
Derivatized peptides have a risk of raising antibodies.
N.B. Please be advised that this press release contains forward-looking statements that involve risks and uncertainties.